Babson Diagnostics recognized for achieving the highest standards in laboratory medicine

AUSTIN, Texas, March 17, 2022–(BUSINESS WIRE)–Babson Diagnostics, a science-driven healthcare technology company, today announced that its laboratory has received accreditation from the College of American Pathologists (CAP) based on results from a recent site inspection.

CAP is a leading healthcare accrediting agency known for its comprehensive and scientifically rigorous standards. Babson’s compliance means the company upholds the highest standards of quality and patient safety in its laboratory practices.

Babson’s Austin lab first received CAP accreditation in 2020. In the renewal application, Babson for the first time demonstrated proficiency in its proprietary testing techniques, a key innovation in its unique technology ecosystem of end-to-end that reinvents blood testing for today’s consumer. Babson built its high-efficiency lab to run large blood panels using one-tenth the sample volume of traditional blood tests. The company has developed miniaturized assays to optimize each microsample.

“We thank the College of American Pathologists Accreditation Committee for their thorough review,” said James Jacobson, Ph.D., vice president of clinical affairs at Babson. “Receiving accreditation reflects our commitment to rigorous scientific evaluation of our innovative testing technologies prior to commercialization of the Babson Blood Testing System.”

The US federal government recognizes CAP’s laboratory accreditation program, initiated in the early 1960s, as equal to or more stringent than the government’s own inspection program.

During the CAP accreditation process, designed to ensure the highest level of care for all patients in the laboratory, inspectors review laboratory records and quality control of procedures from the previous two years. CAP inspectors also review laboratory personnel qualifications, equipment, facilities, safety program and records, and overall management.

“In our journey to make routine blood testing easier, more accessible and less invasive, we innovate with integrity,” said David Stein, Ph.D., CEO of Babson. “Achieving accreditation is another step in our plan to show that our unique ecosystem meets high scientific standards and produces quality diagnostic results that patients and providers can rely on.”

About the College of American Pathologists

As the world’s largest organization of board-certified pathologists and a leading provider of laboratory accreditation programs and proficiency testing, the College of American Pathologists (CAP) serves patients, pathologists, and the public in promoting and advocating excellence in the practice of pathology and laboratory medicine. worldwide. For more information, visit https://www.cap.org.

About Babson Diagnostics

Babson Diagnostics is a science-based health technology company reinventing the complete diagnostic blood testing experience. Babson’s mission is to make routine blood testing less invasive, more convenient and affordable, empowering people to take charge of their health.

Babson will bring medically accurate blood testing to the retail pharmacy using patented technologies and a first-of-its-kind ecosystem that requires only one-tenth the sample volume of traditional venipuncture methods without sacrificing quality, accuracy or the scope of the menu.

The company has been awarded key patents in the United States, European Union and China related to its unique end-to-end technology ecosystem and its ability to maximize the clinical utility of fingertip blood microsamples. Additionally, Babson has fully validated a wide range of miniaturized assays that are ready for commercial use in its CLIA-certified laboratory.

Babson, based in Austin, Texas, was founded by people with deep experience in health technology, diagnostics, engineering and laboratories. It is named in honor of Art Babson, whose legacy of scientific innovation and excellence is the foundation on which the company is built.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220317005032/en/

contacts

Media inquiries only:
Joe Foster
[email protected]
323-572-5361

For general inquiries: [email protected]